P.559 Comparison of possible safety risks on clinical trials between PP3M and PP1M

Autor: Watanabe, S., Masayoshi, T., Hirokazu, K., Ayako, S., Keiko, Y., Midori, T., Akihide, W., Akiko, F.
Zdroj: In European Neuropsychopharmacology November 2020 40 Supplement 1:S317-S318
Databáze: ScienceDirect